Genomics... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genomics...

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (27)	6/22/2000 8:44:00 AM
From: nigel bates	of 360

June 22 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced today the expansion of its multi-year collaboration with Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news). The expanded agreement triples the size of the initial numbers of knockout mouse models that Lexicon will generate for Millennium. ``Knockout mice are increasingly being utilized by major companies in the biopharmaceutical industry as a key resource for the acceleration of drug discovery programs. We believe that knockout-validated genes will become the gold standard for all drug development in the post-genome era,'' said Randall B. Riggs, Sr. Vice President, Business Development of Lexicon Genetics. ``We are pleased to expand our collaboration with Millennium, one of the leaders on the forefront of developing genomics-based medicines for the future.'' Under the original agreement, announced in July 1999, Lexicon Genetics will generate a significant number of knockout mice for Millennium based on gene targets provided by Millennium over a three-year period. The expanded agreement commits Millennium to obtain certain numbers of knockout mice from Lexicon during each year of the collaboration. Additional terms of the arrangement were not disclosed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next